Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 10Neoplasm Metastasis 6Sarcoma 5Liposarcoma 3Inflammatory Breast Neoplasms 3Urinary Bladder Neoplasms 2Leiomyosarcoma 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Refractory Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Metastatic HER2-positive Breast Cancer 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1HER2-negative Metastatic Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Doxorubicin 27pembrolizumab 24Radiotherapy 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Specimen Handling 14Nivolumab 14Ifosfamide 13Gemcitabine 13Biopsy 11Surgical Procedures, Operative 10Radiation 10Temozolomide 9X-Rays 8Ipilimumab 8pazopanib 7fludarabine 7cabozantinib 7Irinotecan 7Blood Specimen Collection 7tazemetostat 6liposomal doxorubicin 6Trabectedin 6Surveys and Questionnaires 6Phantoms, Imaging 6olaparib 5eribulin 5atezolizumab 5Vincristine 5Standard of Care 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Sarcoma × eribulin × 1 year × Clear all
NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed
30 enrolled 9 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06957431 2025-10-24

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Washington University School of Medicine

Phase 1 Recruiting
18 enrolled
Sarcoma

Sarcoma

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

Fudan University

Phase 2 Not yet recruiting
46 enrolled
Sarcoma

Sarcoma

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Dana-Farber Cancer Institute

Phase 2 Completed
57 enrolled 14 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT06263231 2025-07-29

INVINCIBLE-3

Intensity Therapeutics, Inc.

Phase 3 Active not recruiting
333 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡